Drug Trial Radar · NCT06105021
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
Last checked: Nov 19, 2026Latest source record: Jul 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Mar 6, 2024
Primary completion
Dec 2025
Study completion Dec 2029
Sponsor
- Lead sponsor
- Affini-T Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 27, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adult patients with solid tumors who have a KRAS G12V mutation. This mutation is often found in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC) and other cancers. The study is for patients whose cancer has spread through the body and for whom previous treatments were not successful or treatment does not exist. Patients must also be positive for HLA-A\*11:01. The purpose of this study is to find the best dose of AFNT-211 that is safe and can shrink tumors in patients. AFNT-211 is an investigational therapy and this is the first time that AFNT-211 is being administered to patients. AFNT-211 is an autologous T cell product which means that it is made from a patient's own T cells. These cells are engineered and grown to recognize the KRAS G12V protein on the cell surface of cancer cells. AFNT-211 is infused into patients after a short course of lymphodepleting chemotherapy. Patients will frequently visit the study site. The doctors there will regularly check the size of the cancer and the patient's health. They will also take note of any unwanted effects. Patients may continue in this study for as long as they benefit from the treatment.
Conditions
- Pancreatic Ductal Adenocarcinoma
- Non-Small Cell Lung Cancer
- Colorectal Cancer
- Solid Tumor
- KRAS G12V
Interventions
AFNT-211Drug
Engineered TCR T-Cell
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the Optimal Biological Dose (OBD)Time frame: 60 months
- Determine the Recommended Phase 2 DoseTime frame: 60 months
- Incidence of Treatment Emergent Adverse EventsTime frame: 60 months
- Incidence of Serious Adverse EventsTime frame: 60 months
- Incidence of Dose Limiting ToxicitiesTime frame: 18 months
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
USC Norris Comprehensive
Los Angeles, California
University of California Los Angeles Department of Medicine
Los Angeles, California
Yale New Haven Hospital
New Haven, Connecticut
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Providence Cancer Institute Franz Clinic
Portland, Oregon
Sarah Cannon Research Institute
Nashville, Tennessee
MD Anderson Cancer Center
Houston, Texas
Fred Hutchinson Cancer Center
Seattle, Washington
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.